IL1RAP Blockade Weakens Pancreatic Cancer Defenses — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Sylvester Comprehensive Cancer Center researchers found that blocking the IL1RAP receptor disrupts the inflammatory network shielding pancreatic tumors — preclinical studies showed fewer immunosuppressive cells, less fibrosis, and stronger T cell activity.
- Senior author Jashodeep Datta, M.D. described IL1RAP as a shared "helper" receptor that links tumor cells, immune cells, and fibroblasts into a coordinated, treatment-resistant system.
- The study, published in JCI Insight, forms the basis for a planned first-of-its-kind neoadjuvant clinical trial combining IL1RAP targeted therapy with chemoimmunotherapy in patients with operable pancreatic cancer before surgery.
- Co-author Peter Hosein, M.D. said the trial's pre-surgical design lets researchers compare tumor biology before and after treatment, giving an unusually direct window into each patient's response.
- The research is backed by a V Foundation Translational Research Grant worth $800,000 over four years, selected through a national peer-review process.
- The approach addresses an urgent gap: a new KRAS targeted therapy extends survival in metastatic pancreatic cancer but is expected to take years to reach operable cases.
Why it matters: The IL1RAP strategy targets operable pancreatic cancer patients — a group currently underserved because the promising KRAS targeted therapy won't reach them for years. By stripping the tumor's protective environment rather than killing cancer cells directly, the approach aims to make existing chemotherapy and immunotherapy work better in tumors that can still be surgically removed.
Ask SkimNews
